4506 — Sumitomo Pharma Share News
0.000.00%
Last trade - 00:00- ¥826bn
- ¥902bn
- ¥453bn
Brief: Kyorin Holdings Inc, Sumitomo Pharma - Entered Into License Agreement Of Vibegron In Taiwan And Other Asian Countries
Table: Sumitomo Pharma -2022/23 div forecast
Table: Sumitomo Pharma -9-MTH group results (IFRS)
Brief: Mitsui & Co To Buy Sumitomo Pharma Co's Animal Health Unit For More Than 10 Billion Yen - Yomiuri
Brief: Sumitomo Pharma Oncology Presents Preliminary Data From Phase 1/2 Clinical Study Evaluating Investigational Agent Tp-3654 In Patients With Myelofibrosis
Brief: Enzyvant Therapeutics And Altavant Sciences Announce Merger
Japanese shares end higher on positive earnings; Toyota falls
Recorded 49 Billion Yen Gain From FX Rate Fluctuations In Q2 FY2022/23
Table: Sumitomo Pharma -6-MTH group results (IFRS)
Table: Sumitomo Pharma -2022/23 group forecast(IFRS)
U.S. STOCKS ON THE MOVE -Orion,Tesla,Amazon
Japan's Sumitomo Pharma to buy rest of Myovant in sweetened deal (updated)
Myovant Sciences gains on takeover by Sumitomo Pharma
Sumitovant Biopharma to buy Myovant for $27 per share (updated)
Sumitovant Biopharma to buy Myovant for $27 per share
Sumitomo Pharma, Sumitovant Biopharma, And Myovant Sciences Enter Into Definitive Agreement
Brief: Sumitovant Biopharma, Sumitomo Pharma, And Myovant Sciences Enter Into Definitive Agreement
To Post Impairment Loss Of 54.37 Billion Yen In Q2 Associated With Underperforming Treatment Kynmobi
Myovant Science rises after rejecting $2.5 bln buyout bid from Sumitomo Pharma